How effective is denosumab for osteoporosis?

The use of denosumab for osteoporosis seems to be an effective treatment according to the studies that have been performed on it. Compared to placebo and other leading drugs, denosumab has shown to be more effective than placebo and either equally more effective or even more effective than Aendronate. Measurement of the density of bone minerals of patients is performed after treatment with a drug to determine its effectiveness. Denosumab for osteoporosis must also be used only twice a year, which could increase their patient's treatment plans.

Osteoporosis is a condition that causes weakness and fragility in the bones and is therefore usually characterized by common breaks of hips, wrists and spine. The condition is particularly prevailing in women who have undergone menopause, but may also occur in children, men and menopausal women. Although bones are generally considered solid, they are in fact composed of the northern layer of network with hexagonal openings in it. The holes in this network are very small when the bones are healthy but in patients who TrMrs. osteoporosis, these holes are much larger. This reduces bone density and therefore increases the likelihood of bone breaking.

Denosumab is classified as a monoclonal antibody that has been derived from people and primarily affects the Kappa-B Ligand receptor nuclear factor. The drug is primarily intended for the use of women suffering from osteoporosis due to menopause, but is also used in men who have infected osteoporosis due to prostate cancer treatment. Denosumab for osteoporosis is administered in the form of subcutaneous injections twice a year. The level of observing osteoporosis treatment regimens is very low, only about one quarter of the patients adhere to the plan and relapids low injecting is a denosumab attractive prospect.

Many studies have been performed on the effects of denosumab for osteoporosis in menopausal women. Scientists looked at the number of fractures that occurred during the treatment period and recorded Hthe Ustot of the Bones of Patients. Denosumab was also compared with Alendronate, common medication of bisphosphonate osteoporosis and placebo. Overall, it has been shown that denosumab works better than placebo and slightly better than Alendronate.